Photopheresis for antibody-mediated rejection in kidney transplant
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study looks at how well extracorporeal photopheresis (a treatment that filters and treats your blood with light) works for kidney transplant patients who have antibody-mediated rejection (when your immune system attacks the new kidney). It may help doctors understand if this treatment can stop the rejection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a kidney transplant between September 2016 and August 2023 at the University Hospitals of Besançon or Lille in France.
- You were diagnosed with antibody-mediated rejection confirmed by a kidney biopsy.
- You received extracorporeal photopheresis to treat the rejection.
- You do not object to your medical data or samples being used for research.
- You are covered by French social security or health insurance.
- You are not pregnant, breastfeeding, or in prison.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether extra body light treatment (ECP) can change certain immune cells in people with a specific type of kidney transplant rejection caused by antibodies (cABMR). It’s meant to see if ECP could help manage the immune process after transplant.
This study looks at how the body’s immune system responds when a kidney transplant shows signs of rejection, using a planned kidney biopsy. It may help doctors better understand what drives rejection and how to improve care in the future.
This trial tests a new approach to treat T-cell mediated rejection in kidney transplant recipients. It aims to safely and effectively stop the rejection episode.
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
This trial tests whether a therapy called extracorporeal photopheresis (ECP) can stop early, silent rejection in lung transplant patients. It is for people who have developed donor-specific antibodies but still have normal lung function.
This trial tests a drug called BiTE to reduce high antibody levels (cPRA ≥90%) in people waiting for a kidney transplant. If it works, it might help you become eligible for a transplant sooner.
Hear when a new Antibody-mediated Rejection in Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.